Genetic, structural and clinical analysis of spastic paraplegia 4

Parizad Varghaei^{1,2}, MD, Mehrdad A Estiar^{2,3}, MSc, Setareh Ashtiani⁴, MSc, Simon Veyron⁵, PhD, Kheireddin Mufti^{2,3}, MSc, Etienne Leveille⁶, MD, Eric Yu^{2,3}, BSc, Dan Spiegelman, MSc², Marie-France Rioux⁷, MD, Grace Yoon⁸, MD, Mark Tarnopolsky⁹, MD, PhD, Kym M. Boycott¹⁰, MD, Nicolas Dupre^{11,12}, MD, MSc, Oksana Suchowersky^{4,13}, MD, Jean-François Trempe⁵,PhD, Guy A. Rouleau^{2,3,14}, MD, PhD, Ziv Gan-Or^{2,3,14}, MD, PhD

- 1. Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Ouebec, Canada
- 2. The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Ouebec, Canada
- 3. Department of Human Genetics, McGill University, Montréal, Québec, Canada
- 4. Alberta Children's Hospital, Medical Genetics, Calgary, Alberta, Canada
- 5. Department of Pharmacology & Therapeutics and Centre de Recherche en Biologie Structurale FRQS, McGill University, Montréal, Canada
- 6. Faculty of Medicine, McGill University, Montreal, QC, Canada
- 7. Department of Neurology, Université de Sherbrooke, Sherbrooke, Québec, Canada.
- 8. Divisions of Neurology and Clinical and Metabolic Genetics, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada
- 9. Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
- 10. Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada
- 11. Department of Medicine, Faculty of Medicine, Université Laval, Québec City, Quebec, Canada
- 12. Neuroscience Axis, CHU de Québec-Université Laval, Québec City, Québec, Canada
- 13. Departments of Medicine (Neurology) and Medical Genetics, University of Alberta, Edmonton, Alberta, Canada
- 14. Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada

Correspondence to:

Guy A. Rouleau,

Director, Montréal Neurological Institute and hospital,

Address: 3801, University Street, Office 636

Montréal, Québec H3A 2B4 Phone: +1-514-398-2690, Fax. +1-514 398-8248

Email: guy.rouleau@mcgill.ca

Ziv Gan-Or

Department of Neurology and Neurosurgery McGill University 1033 Pine Avenue, West, Ludmer Pavilion, room 312 Montreal, QC, H3A 1A1,

Phone: +1-514-398-5845

Fax. +1-514 398-8248

Email: ziv.gan-or@mcgill.ca

Keywords: Spastic paraplegia, HSP, SPG4, SPAST

Relevant conflicts of interest/financial disclosures: The authors report no competing interests.

Funding sources for the study: This study was funded by CIHR Emerging Team Grant, in

collaboration with the Canadian Organization for Rare Disorders (CORD), grant number

RN127580 – 260005, and by a CIHR Foundation grant granted to GAR. MAE is funded by the

Fonds de Recherche du Québec-Santé (FRQS). GAR holds the Wilder Penfield Chair in

Neurosciences. ZGO is supported by the Fonds de recherche du Québec-Santé Chercheur-

2

Boursier award and is a William Dawson Scholar.

Abstract

Introduction Spastic paraplegia type 4 (SPG4), resulting from heterozygous mutations in the

SPAST gene, is the most common form among the heterogeneous group of hereditary spastic

paraplegias (HSPs). We aimed to study genetic and clinical characteristics of SPG4 across

Canada.

Methods The SPAST gene was analyzed in a total of 696 HSP patients from 431 families by

either HSP-gene panel sequencing or whole exome sequencing (WES). We used Multiplex

ligation-dependent probe amplification to analyze copy number variations (CNVs), and

performed in silico structural analysis of selected mutations. Clinical characteristics of patients

were assessed, and long-term follow-up was done to study genotype-phenotype correlations.

Results We identified 157 SPG4 patients from 65 families who carried 41 different SPAST

mutations, six of which are novel and six are CNVs. We report novel aspects of mutations

occurring in Arg499, a case with homozygous mutation, a family with probable compound

heterozygous mutations, three patients with de novo mutations, three cases with pathogenic

synonymous mutation, co-occurrence of SPG4 and clinically isolated syndrome, and novel or

rarely reported signs and symptoms seen in SPG4 patients.

Conclusion Our study demonstrates that SPG4 is a heterogeneous type of HSP, with diverse

genetic features and clinical manifestations. In rare cases, biallelic inheritance, de novo mutation,

3

pathogenic synonymous mutations and CNVs should be considered.

Introduction

Spastic paraplegia type 4 (SPG4, OMIM #182601) is the most frequent form of hereditary spastic paraplegias (HSPs), caused by heterozygous mutations in the *SPAST* gene. With more than 80 potentially causative loci or genes reported to date, HSPs are known to affect about 1.8/100,000 of the population,¹ and autosomal dominant (AD) HSPs comprise 43%-80% of them.^{2, 3} Among all AD-HSPs, 70-80% are categorized as "pure" with a phenotype limited to pyramidal signs in the lower limbs, with or without deep sensory loss and sphincter disturbances.¹ Of all pure AD-HSPs, about 40% are caused by *SPAST* mutations.¹

SPAST encodes spastin, which is a protein from the AAA (ATPase associated with various cellular activities) family of ATPases. Spastin controls different aspects of microtubule dynamics (e.g. microtubule number, motility, length, disassembly and remodeling), and hydrolyses ATP to cleave microtubules, a necessary step in axonal transport.^{4, 5} The structure of human spastin residues 323-610 was solved by cryoelectron microscopy revealing an AAA+ ATPase homohexamer (Figure 1A), with ATPase active sites located at the interface between every adjacent subunit (Figure 1B).^{5, 6}

To date, more than 200 *SPAST* mutations have been found.⁷. Exon deletions may account for 20% of cases in whom point mutations are not detected.⁸

The penetrance of SPG4 is up to 80-90% and is age-dependent, with age at onset (AAO) that may range from infancy to the eighth decade of life. Most cases present as juvenile or adult-onset pure spastic paraplegia with urinary sphincter disturbances, and pes cavus. However, SPAST mutations are known to cause clinically heterogeneous manifestations, and a high interfamilial and intrafamilial variety of signs and symptoms is reported.

Although previous studies have deciphered some aspects of this variability, the genotype-

phenotype correlations and some rare features of SPG4 are not fully understood. In this study,

we analyzed a large cohort of SPG4 patients from Canada to better clarify the genetic and

clinical spectrum of the disease.

Methods

Population

A total of 696 HSP patients from 431 families were recruited in eight medical centers across

Canada (Montreal, Quebec, Ottawa, Toronto, Hamilton, Calgary, Edmonton, and Vancouver) as

part of CanHSP, a Canadian consortium for the study of HSP. Details about the diagnosis and

recruitment process has been previously reported. 10 Clinical assessments were done and for a

subset of 28 patients, the Spastic Paraplegia Rating Scale (SPRS) was measured. . For another

subset of patients, brain and/or spine MRI were performed. All patients signed informed consent

forms and the institutional review boards approved the study protocol.

Genetic and data analysis

DNA was extracted from peripheral blood using a standard procedure. Initially, HSP-gene panel

sequencing was performed on 379 patients. Then, 194 genetically undiagnosed patients, and

additional 206 patients who were not analyzed with panel sequencing (400 patients in total from

291 families), went through whole exome sequencing (WES).

For WES, the Agilent SureSelect Human All Exon v4 kit for capture and targeted

enrichment of the exome was used. To analyze the WES data, we used a list of 785 HSP-related

genes or genes associated with similar neurological disorders which cause spasticity (Supplementary Table 1). Illumina HiSeq 2000/2500/4000 system was used for sequencing. Using Burrows-Wheeler Aligner (BWA), the sequence reads were then aligned against the human genome (GRCh37 assembly). We used the Genome Analysis ToolKit (GATK) and Annotate Variation (ANNOVAR) for variant calling and annotation, respectively. We excluded variant calls with a genotype quality less than 97 and less than 30x depth of coverage. Integrated Genomics Viewer was used to visually inspect the detected variants, and suspicious variants were validated by Sanger Sequencing. Sanger Sequencing was also used for assessing sporadic

patients' parents, to determine if the proband had a *de novo* mutation.

SPAST variants (NM_014946) were initially selected based on identifying missense and LoF alleles, including frame-shift, splice-site, nonsense, and copy number variations (CNVs) with a minor allele frequency less than 0.01 in gnomAD. The variants' pathogenicity has been determined using VarSome, according to the American College of Medical Genetics and Genomics (ACMG) guideline. Variants classified as "Benign" and "Likely Benign", as well as intronic splice site variants higher than ±3 were excluded from the analysis. To detect CNVs, ExomeDepth¹¹ was used on WES data, followed by 48 selected samples that went through Multiplex ligation-dependent probe amplification (MLPA) testing (MRC Holland, Amsterdam, The Netherlands) to confirm or exclude suspected *SPAST* CNVs. InterPro¹² was applied to identify domains and corresponding sites in the protein.

Statistical analysis

To determine the association between two categorical variables, one categorical variable with one continuous variable, and two continuous variables, Pearson chi-squared test, Mann-Whitney U test, and Spearman's rank correlation coefficient were used, respectively. *P*-values were

adjusted for false discovery rate (FDR) correction as the variables were not always independent.

All P-values were considered as significant if <0.05. SPSS was used to perform all statistical

analyses.

In silico structural analysis

The atomic coordinates of human spastin bound to a glutamate-rich peptide, ADP, BeF₃ and

Mg²⁺ and D. melanogaster spastin bound to a glutamate-rich peptide, ADP, ATP and Mg²⁺were

downloaded from the Protein Data Bank (ID 6PEN and 6P07). The effect induced by each

mutation was evaluated using the "mutagenesis" toolbox in The PyMOL Molecular Graphics

System, Version 2.4.0 Schrödinger, LLC. and the DynaMut server

http://biosig.unimelb.edu.au/dynamut/.

Results

Cohort characteristics

We identified 65 families (15.1% of all HSP families), and a total of 157 patients (22.5% of HSP

patients) with SPG4. Mean AAO was 22 years (0-67, SD: 19.89), with a bimodal distribution;

the first peak in the first 5 years of life, and the second peak from 35 to 44 years of age

(Supplementary Figure 1). Age at onset was not associated with the severity of the disease

(Spearman's correlation coefficient; p = 0.934). Complex HSP was seen in 24/65 (36.9%) of the

probands, and 37/157 (23.6%) of all the patients. No significant clinical differences were seen

7

between male and females. Table 1 details the clinical presentation of the patients.

We detected 41 different *SPAST* mutations in our cohort (Table 2). Most mutations (22/34, 64.7%) occurred between amino acids 374 and 567, in the AAA cassette. Among the missense mutations, 15/20 (75%) were clustered in AAA cassette, while LoF mutations were more evenly distributed across gene (Supplementary Figure 2). Presentation of the disease did not differ significantly between the two types of mutation (Table 1).

Novel SPAST mutations

Of the 41 different *SPAST* mutations in our cohort, six were novel, including p.(Trp77Ter), p.(Glu366AspfsTer28), p.(Gly382_Pro383insArg), p.(Phe403Leu), p.(Arg498AlafsTer30), and p.(Ser597ThrfsTer3). We performed *in silico* analysis to investigate the impact of these mutations on the structure and activity of spastin, with exception of p.(Trp77Ter), as Trp77 is not visible in any structure of spastin.

Glu366 is located in the loop₃₆₅₋₃₇₇ and the frameshift mutation p.(Glu366AspfsTer28) changes all the residue subsequent to residue 365 and inserts a stop codon at position 394. This mutation truncates residues 394-616 which includes residues involved in oligomerization and ATP-binding, which will abrogate its enzymatic activity. Gly382 and Pro383 are located in the nucleotide-binding loop₃₈₂₋₃₈₉.¹³ Residues Gly385 and Asn386 interact directly with the ADP, in a conformation that is shaped by the Pro383 and Pro384 (Figure 1C). The mutation p.(Gly382_Pro383insArg) lengthens this loop and likely destabilizes the interaction between the protein and the nucleotide. Phe403 forms a pi-stacking interaction with Phe439 and hydrophobic interactions with neighbouring residues (Figure 1D). Thus, mutation p.(Phe403Leu) would destabilize the domain and impair the ATPase activity.

In this structure, Arg498 and Arg499 are both involved in coordinating ADP. Arg498 is making direct interaction with the β phosphate of the nucleotide located in the active site, while Arg499 stabilizes helix₄₅₅₋₄₇₀ and coordinates BeF₃, a phosphate structural analog (Figure 1E). By homology with *D. melanogaster* spastin structure (PDB ID: 6P07), those residues seem to be also involved in ATP β and γ phosphate coordination (Figure 1F). As a result, we can hypothesize that the BeF₃ in the active site is mimicking the γ phosphate on an ATP. Mutation p.(Arg498AlafsTer30) causes residues 498 and 499 to be serine and valine residues, which would prevent ATP stabilization. In addition, this frame shift terminates the protein after residue 528, further disrupting the ATP-binding domain. This mutation will therefore abolish the ATPase activity. Finally, mutation p.(Ser597ThrfsTer3) will induce a frame shift at residue 597 and truncate the protein at residue 600. The missing C-terminal residues form a helix involved in intersubunit interactions. This mutation would therefore destabilize the hexameric assembly, which would disrupt the ATPase activity.

Founder French-Canadian mutations and known CNVs

The most frequent *SPAST* mutation in our cohort, p.(Gly559Asp), previously suggested to be a founder mutation in French-Canadian population¹⁴, was carried by 8 families (12.3%) and 15 patients in total (9.5%). Seven out of 24 French-Canadian probands (29%) harbored this mutation, while among all the patients with other or unknown ancestral backgrounds, this mutation was present in only one out of 29 probands (3.4%, p=0.011). Moreover, the mutation p.(Phe403Leu) was only detected in patients with French-Canadian ancestral background, in 5 patients from 2 families, suggesting it may be a founder mutation. Seven patients (4.5%) from

six families (9.2%) carried a CNV (Supplementary Table 2), all of which have been previously

reported. 8

Earlier age at onset and specific clinical features in patients with mutations in SPAST

p.Arg499

The range of AAO in all 4 patients from 4 different families, two of which have previously been

reported¹⁵ with the p.(Arg499His) mutation was 1-3 years (Mann-Whitney U test; p = 0.003).

Patients with this mutation in our cohort were more likely to present with motor delay, speech

delay, dysarthria, learning disability, progressive cognitive deficits, and upper extremity

weakness (Supplementary Table3).

Although statistically insignificant, cases who carried another mutation affecting the

same amino acid residue, p.(Arg499Cys), also showed symptoms at a younger age (the range of

AAO was 1-5 in three patients and 11-15 in one patient, p = 0.111). When combined together,

the two mutations occurred in Arg499 locus were associated with a younger AAO (Mann-

Whitney U test; p = 0.004). In silico analysis of Arg499 is discussed above, along with Arg498.

Furthermore, as Arg499 stabilizes the γ phosphate, mutations p.(Arg499Cys) or p.(Arg499His)

would also impede ATP binding and catalysis.

Possible biallelic inheritance in SPG4

The SPAST p.(Ser44Leu) variant has been previously suggested to play modifier role in SPG4. 16,

¹⁷ This variant was detected in one out of the 36 families that had undergone WES. From the

three affected siblings, two had undergone WES, and both were heterozygous for the novel

pathogenic mutation p.(Ser597ThrfsTer3), as well as for the p.(Ser44Leu) variant. The three

siblings had complex HSP with disease onset in early childhood (clinical presentation of these

patients is detailed in Supplementary Table 4). One unaffected parent only carried the

p.(Ser44Leu) polymorphism, and the other unaffected parent was heterozygous for the

pathogenic p.(Ser597ThrfsTer3) mutation and wild-type for p.(Ser44Leu) (Supplementary Figure

3). The last physical examination of the parent with the pathogenic mutation at the age between

56 to 60 revealed completely normal findings, Supporting the possible role of p.(Ser44Leu)

variant as a modifier, or suggesting that extreme anticipation with undetected clinical effects in

the mother could exist in this family.

Another patient with consanguineous parents, carried a homozygous mutation, SPAST

p.(Tyr51Ter). The patient had started to show symptoms at an age range of 1-5 years and

suffered from core HSP symptoms, motor and speech delay, swallowing difficulty, dysarthria,

upper extremity weakness, pes cavus, and skeletal abnormalities. Her brain and total spine MRI

were normal and her SPRS score was 40 when examined at an age between 16 and 20 years. The

patient's parents were both asymptomatic heterozygous carriers.

Patients with novel or rarely reported clinical manifestations

In our cohort, four patients we report patients with deafness, ocular movement abnormality,

11

upper extremity intention tremor, and seizure (Supplementary Table 5).

De novo cases

The parents of the three sporadic cases in our cohort did not carry the causative *SPAST* mutations. The first patient, with *SPAST* p.(Ser407Asn), had an AAO of 1-5 years. This case presented with lower extremity weakness and spasticity, upper and lower limb hyperreflexia, extensor plantar response, ankle clonus, and sensory abnormalities. They also showed signs of upper extremity weakness, motor and speech delay, dysarthria, learning disability, and swallowing difficulty. Their brain MRI was normal. The second patient had *de novo SPAST* p.(Arg499His). This patient started to show symptoms at age range of 1-5, and her symptoms included lower extremity weakness, spasticity and hyperreflexia, extensor plantar responses, and ankle clonus. Furthermore, they had motor and speech delay, dysarthria, and learning disability. They had a normal brain MRI, and their SPRS score was 37. The last *de novo* patient, also with a p.(Arg499His) mutation, also with an AAO range of 1-5 years, had an SPRS score of 28, and apart from core symptoms of HSP, had motor and speech delay, deafness, and dysarthria. The two latter patients have been previously reported.¹⁵

Cases with synonymous mutation and co-occurrence of clinically isolated syndrome (CIS)

and SPG4

We report three patients from two unrelated families who carried the synonymous mutation *SPAST* p.(Lys414Lys), previously reported to be pathogenic. The first patient had an AAO of between 6-10 years, and presented with lower extremity spasticity, hyperreflexia, and extensor plantar responses. The second family had two affected individuals, parent and offspring. The parent started to have difficulty walking at the age of 61-65 which led to using a cane, had marked spasticity and brisk reflexes in the lower limbs along with ankle clonus, upgoing plantar responses, urge incontinency, and mild decrease of vibration sensation in the ankles and toes.

The offspring noticed difficulty walking at 21-25 years of age, which progressed slowly. This case had upper and lower limb weakness, bilateral Babinski sign and ankle clonus, and positive Hoffman sign. At an age between 31 and 35, lumbar puncture carried out due to diplopia was positive for oligoclonal bands and suggested a diagnosis of clinically isolated syndrome (CIS), which is considered as the first clinical episode in multiple sclerosis (MS). They were treated with methylprednisone, and after one month, the diplopia resolved. In addition to this patient

described, two demonstrate unaffected family members who have a definite or probable

who is a case of co-occurrence of SPG4 and CIS, from the 10 pedigrees of the families

diagnosis of MS.

Discussion

In this large-scale analysis of SPG4 from CanHSP, we report novel *SPAST* mutations, the possibility of a founder mutations in the French-Canadian population, novel characteristics of mutations occurring in Arg499, and potential biallelic inheritance. We also report patients with rare or novel clinical manifestations, and co-occurrence of SPG4 and CIS.

Using *in silico* analysis, we predict that the novel mutations reported in this study cause a loss-of-function of spastin, either by substantially shortening the protein, affecting its ATPase activity, or disturbing the formation of a ternary and quaternary structure necessary for catalysis. Spastin, a microtubule-cleaving enzyme involved in the cytoskeletal rearrangement, also has a role in intracellular trafficking, cytokinesis regulation and resealing of nuclear membrane. In neurons, it is involved in the regeneration of axons and axonal transport. Mutations in *SPAST*

could result in a disruption of normal organelle trafficking and distribution, and thus microorganelle accumulation in axons and swelling of axons which could result in HSP phenotype. 4, 5,

20-22 We looked further into the three patients identified as sporadic and found out that all carried *de novo* mutations. Consistent with previous reports of more severe manifestations in patients with *de novo* mutations, 23 all patients showed a severe form of the disease. However, it is important to note that the mutation in two of the *de novo* patients (Arg499His), which is also carried by 33% of *de novo* patients, 23 is associated with a younger AAO. It has been suggested that amino acid 499 is located in one of the highly conserved regions of the *SPAST* gene, 24 and mutations that occur in this region could have a significant effect on the hydrophobicity of the protein and its ability to sever microtubules. 15

The mutation in our homozygous patient has been reported previously in a heterozygous patient;²⁵ however, the presence of an additional mutation or CNVs could not have been determined in that study. Our patient with the homozygous mutation *SPAST* p.(Tyr51Ter) showed a severe form of the disease. Previously, there have been two reports of homozygous variants in *SPAST*. One, with the nonsense mutation p.(Ser545Ter), which also reports a complex and severe form of the disease,²⁶ and another, with the mutation p.(Leu534Pro), who showed a pure spastic paraparesis at the age of 39.²⁷ The patient from our cohort and the previously reported patient with p.(Ser545Ter) presented with a more severe form of the disease, probably because they carried nonsense mutations, while the latter patient had a missense mutation. Furthermore, in the latter study, the parents of the proband were asymptomatic carriers of the mutation.

The mode of inheritance observed in the patient with homozygous mutation and the family carrying the potential modifier mutation *SPAST* p.(Ser44Leu), may be explained by

incomplete penetrance and/or anticipation rather than biallelic inheritance, which could be considered in prenatal diagnosis and genetic counselling. The synonymous mutation *SPAST* p.(Lys414Lys) we report in three patients has been previously reported to underlie the disease, and minigene assay suggested that this variant leads to an aberrant splicing effect.¹⁸ It is therefore important to not exclude synonymous variants when analyzing HSP specifically and other diseases in general.

The AAO distribution in our cohort followed the same trend as previously reported. ^{16, 25} We did not find an association between mutation type, sex, or late onset, with the disease course. In our data, we did not find an association between mutation type, sex, or late onset, with the disease course. Table 3 compares the frequency of symptoms not attributable to pure form of the disease in our cohort with previous studies. We report deafness in SPG4 for the first time. The co-occurrence of SPG4 and MS has been reported before; ^{28, 29} however, the results of studies assessing an association between HSP-related mutations and MS are controversial and further studies are required to verify such a relation.

Our study has several limitations. For instance, in spite of being one of the largest HSP cohorts, the number of SPG4 patients was limited, especially for a genotype-phenotype correlation study. Furthermore, the families interested in participating in this study were probably those who had remained undiagnosed after the primary *SPAST* testing; therefore, the proportion of SPG4 patients in this study may be underestimated. In addition, clinical signs and symptoms for some of the patients were missing and as the study was not longitudinal, from the patients whose clinical data were collected, little follow up information was available. Also, not all comorbidities such as psychiatric disorders were assessed.

In conclusion, we report one of the largest SPG4 cohorts, with 41 different mutations

including 6 novel mutations. We suggest that modes of inheritance other than autosomal

dominant could be involved in SPG4. Our study sheds light on some rarely reported or

unreported aspects of the disease and helps improve genetic counseling and clinical trials

conducted on SPG4. Towards this goal, larger efforts and international collaborations are

required.

Acknowledgments: We thank the patients and their families for participating in this study. We

thank Patrick Dion, Daniel Rochefort, Helene Catoire, and Vessela Zaharieva for their

assistance.

Patient consent for publication: Not required

Funding: This study was funded by CIHR Emerging Team Grant, in collaboration with the

Canadian Organization for Rare Disorders (CORD) [grant number RN127580 – 260005]; and by

a CIHR Foundation grant granted to GAR. MAE is funded by the Fonds de Recherche du

Québec-Santé (FRQS). GAR holds the Wilder Penfield Chair in Neurosciences. ZGO is

supported by the Fonds de recherche du Québec-Santé Chercheur-Boursier award and is a

William Dawson Scholar.

Data availability statement: All data relevant to the study are included in the article or

uploaded as online supplemental information. Anonymised data, materials and detailed protocols

are available from the corresponding author on reasonable request.

Contributors: P.V.: Research project conception, organization, and execution; statistical

analysis design and execution, writing of first draft. M.A.E.: Research project conception,

organization and execution; manuscript review and critique. S.A., M.F.R., G.Y., M.T., K.M.B., N.D., O.S., and E.L.: Patient recruitment and data collection. E.L, E.Y, DS, S.V., and J.F.T.: Data analysis. K.F.: Manuscript preparation. G.A.R.: Research project conception and organization; manuscript review and critique. Z.G.O.: Research project conception and organization; statistical analysis design, review and critique; manuscript review and critique.

References

- 1. Blackstone C. Hereditary spastic paraplegia. Handbook of clinical neurology 2018;148:633-652.
- 2. Hedera P. Hereditary spastic paraplegia overview. GeneReviews®[Internet] 2021.
- 3. Schüle R, Wiethoff S, Martus P, et al. Hereditary spastic paraplegia: clinicogenetic lessons from 608 patients. Annals of neurology 2016;79(4):646-658.
- 4. Zehr E, Szyk A, Piszczek G, Szczesna E, Zuo X, Roll-Mecak A. Katanin spiral and ring structures shed light on power stroke for microtubule severing. Nature structural & molecular biology 2017;24(9):717-725.
- 5. Sandate CR, Szyk A, Zehr EA, Lander GC, Roll-Mecak A. An allosteric network in spastin couples multiple activities required for microtubule severing. Nature structural & molecular biology 2019;26(8):671-678.
- 6. Zehr E, Szyk A, Piszczek G, Szczesna E, Zuo X, Roll-Mecak A. Katanin spiral and ring structures shed light on power stroke for microtubule severing. Nature structural & molecular biology 2017;24(9):717.
- 7. Shoukier M, Neesen J, Sauter SM, et al. Expansion of mutation spectrum, determination of mutation cluster regions and predictive structural classification of SPAST mutations in hereditary spastic paraplegia. European journal of human genetics 2009;17(2):187-194.
- 8. Depienne C, Fedirko E, Forlani S, et al. Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia. Journal of medical genetics 2007;44(4):281-284.
- 9. Solowska JM, Baas PW. Hereditary spastic paraplegia SPG4: what is known and not known about the disease. Brain 2015;138(9):2471-2484.
- 10. Chrestian N, Dupré N, Gan-Or Z, et al. Clinical and genetic study of hereditary spastic paraplegia in Canada. Neurology Genetics 2017;3(1).
- 11. Plagnol V, Curtis J, Epstein M, et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics 2012;28(21):2747-2754.
- 12. Mitchell AL, Attwood TK, Babbitt PC, et al. InterPro in 2019: improving coverage, classification and access to protein sequence annotations. Nucleic acids research 2019;47(D1):D351-D360.
- 13. Evans KJ, Gomes ER, Reisenweber SM, Gundersen GG, Lauring BP. Linking axonal degeneration to microtubule remodeling by Spastin-mediated microtubule severing. The Journal of cell biology 2005;168(4):599-606.
- 14. Meijer IA, Dupré N, Brais B, et al. SPG4 founder effect in French Canadians with hereditary spastic paraplegia. Canadian journal of neurological sciences 2007;34(2):211-214.
- 15. Gillespie MK, Humphreys P, McMillan HJ, Boycott KM. Association of early-onset spasticity and risk for cognitive impairment with mutations at amino acid 499 in SPAST. Journal of child neurology 2018;33(5):329-332.
- 16. Parodi L, Fenu S, Barbier M, et al. Spastic paraplegia due to SPAST mutations is modified by the underlying mutation and sex. Brain 2018;141(12):3331-3342.
- 17. Svenson IK, Kloos MT, Gaskell PC, et al. Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations. Neurogenetics 2004;5(3):157-164.
- 18. Svenson IK, Ashley-Koch AE, Gaskell PC, et al. Identification and expression analysis of spastin gene mutations in hereditary spastic paraplegia. The American Journal of Human Genetics 2001;68(5):1077-1085.
- 19. Sorensen PS, Sellebjerg F, Hartung H-P, Montalban X, Comi G, Tintoré M. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain 2020;143(9):2637-2652.

- 20. Boutry M, Morais S, Stevanin G. Update on the genetics of spastic paraplegias. Current neurology and neuroscience reports 2019;19(4):1-19.
- 21. Denton KR, Lei L, Grenier J, Rodionov V, Blackstone C, Li XJ. Loss of spastin function results in disease-specific axonal defects in human pluripotent stem cell-based models of hereditary spastic paraplegia. Stem cells 2014;32(2):414-423.
- 22. Fassier C, Tarrade A, Peris L, et al. Microtubule-targeting drugs rescue axonal swellings in cortical neurons from spastin knockout mice. Disease models & mechanisms 2013;6(1):72-83.
- 23. Schieving JH, de Bot ST, van de Pol LA, et al. De novo SPAST mutations may cause a complex SPG4 phenotype. Brain 2019;142(7):e31-e31.
- 24. Errico A, Ballabio A, Rugarli El. Spastin, the protein mutated in autosomal dominant hereditary spastic paraplegia, is involved in microtubule dynamics. Human molecular genetics 2002;11(2):153-163.
- de Bot ST, van den Elzen RT, Mensenkamp A, et al. Hereditary spastic paraplegia due to SPAST mutations in 151 Dutch patients: new clinical aspects and 27 novel mutations. Journal of Neurology, Neurosurgery & Psychiatry 2010;81(10):1073-1078.
- 26. Cruz-Camino H, Vázquez-Cantú M, Vázquez-Cantú DL, et al. Clinical Characterization of 2 Siblings with a Homozygous SPAST Variant. The American Journal of Case Reports 2020;21:e919463-919461.
- 27. de Bot ST, Van Den Elzen R, Mensenkamp A, et al. Hereditary spastic paraplegia due to SPAST mutations in 151 Dutch patients: new clinical aspects and 27 novel mutations. Journal of Neurology, Neurosurgery & Psychiatry 2010;81(10):1073-1078.
- 28. Boucher JJ, Counihan TJ. Co-incident primary progressive multiple sclerosis and hereditary spastic paraplegia (SPG4)—a case report. Multiple Sclerosis and Related Disorders 2020;44:102375.
- 29. Mead S, Proukakis C, Wood N, Crosby A, Plant G, Warner T. A large family with hereditary spastic paraparesis due to a frame shift mutation of the spastin (SPG4) gene: association with multiple sclerosis in two affected siblings and epilepsy in other affected family members. Journal of Neurology, Neurosurgery & Psychiatry 2001;71(6):788-791.

Supplementary Tables and Figures

Supplementary Table 1. Genes that are known or suspected to be involved in HSP or other

similar disorders.

Supplementary Table 2. Copy number variations (CNVs) in the current study.

Supplementary Table 3. Signs and symptoms seen more frequently in patients harboring the

p.(Arg499His) mutation.

Supplementary Table 4. Clinical manifestations of the family with probable biallelic

inheritance. Patients 1 and 2 had undergone whole exome sequencing and were compound

heterozygous carriers of the novel pathogenic mutation p.(Ser597ThrfsTer3), and the

p.(Ser44Leu) variant. Sample from patient 3 was not available.

Supplementary Table 5. Characteristics of SPG4 patients with deafness.

Supplementary Figure 1. Distribution of age at onset in the cohort. The onset of SPG4

mostly occurs in the first five years of life, and between 35-44 years of age.

Supplementary Figure 2. Schematic figure of the location of SPG4 mutations in the current

study. The schematic on top represents the spastin protein. Functional domains are demonstrated

in different colors, including MIT (violet), AAA-ATPase (red), AAA-lid-3 (cyan), and Ps4-C

(yellow). Mutations resulting in loss of function and missense mutations are indicated with red


and grey circles respectively. The number of circles in a column demonstrate the number of

families that carried each mutation. The bottom schematic represents the cDNA of SPG4. Exons

20

(indicated with Ex) are represented by dark blue and introns by light blue.

Supplementary Figure 3. Sanger sequencing results of family with modifier mutation. Mother and father carry the p.(Ser597ThrfsTer3) and p.(Ser44Leu) mutations respectively. Siblings are heterozygote for both mutations.



| nical | Frequency | Gender | | | Type of mutation | | | Protein Domain (Missense mutations) | | | | |
|------------|-----------|--------|--------|--------|------------------|-------------------|--------|-------------------------------------|-------------------------|------------------------|---------------------|---------|
| esentation | | | | | | | | | | | | |
| | | Male | Female | p | LoF | Missense(n=20/41) | p | MIT ^a | AAA_ATPase ^b | AAA_lid_3 ^c | Vps4_C ^d | Other |
| | | (n=72, | (n=85, | value* | (n=21/41) | | value* | | | | _ | domains |

Table 1. Frequency of signs and symptoms among different categories of gender, mutation type and protein domain.

| (2.6%) 1/38 (2.6%) 1/37 (2.7%) 3/38 (7.9%) 7/38 (18.4%) 3/38 (7.7%) | .749 .749 .749 .756 .756 .901 .902 | (5.3%) - 1/19 (5.3%) 0/19 (0%) 0/20 (0%) 3/20 (15%) 0/19 (0%) 11/21 (52.4%) Type of m | 0/41 (0%) 4/41 (9.8%) 4/40 (10%) 8/41 (19.5%) 4/41 (9.8%) | .648 .648 .648 .901 .648 | Protein | 2/27 (7.4%) 3/27 (11.1%) 6/27 (22.2%) 3/27 (11.1%) 8/27 (29.6%) | - 0/6 (0%) 0/6 (0%) 1/6 (16.7%) 0/6 (0%) 3/9 (33.3%) | - - 1/1 (100%) 0/1 (0%) 0/1 (0%) 0/1 (0%) 1/1 (100%) | 1/7 (14.3%) 1/6 (16.7%) 1/7 (14.3%) 1/7 (14.3%) 3/7 (42.9%) |
|---|--|---|--|---|--|--|--|--|--|
| (2.6%) 1/38 (2.6%) 1/37 (2.7%) 3/38 (7.9%) 7/38 (18.4%) 3/38 (7.7%) 16/41 | .749 .749 .749 .756 .756 .901 .902 | 1/19 (5.3%) 0/19 (0%) 0/20 (0%) 3/20 (15%) 0/19 (0%) | 0/41 (0%) 4/41 (9.8%) 4/40 (10%) 8/41 (19.5%) 4/41 (9.8%) | .648 .648 .648 .901 | - | - 2/27 (7.4%) 3/27 (11.1%) 6/27 (22.2%) 3/27 (11.1%) | - 0/6 (0%) 0/6 (0%) 1/6 (16.7%) 0/6 (0%) | - 1/1 (100%) 0/1 (0%) 0/1 (0%) 0/1 (0%) | 1/7 (14.3%) 1/6 (16.7%) 1/7 (14.3%) 1/7 (14.3%) |
| (2.6%) 1/38 (2.6%) 1/37 (2.7%) 3/38 (7.9%) 7/38 (18.4%) 3/38 (7.7%) 16/41 | .749 .749 .749 .756 .756 .901 .902 | 1/19 (5.3%) 0/19 (0%) 0/20 (0%) 3/20 (15%) 0/19 (0%) | 0/41 (0%) 4/41 (9.8%) 4/40 (10%) 8/41 (19.5%) 4/41 (9.8%) | .648 .648 .648 .901 | - | - 2/27 (7.4%) 3/27 (11.1%) 6/27 (22.2%) 3/27 (11.1%) | - 0/6 (0%) 0/6 (0%) 1/6 (16.7%) 0/6 (0%) | - 1/1 (100%) 0/1 (0%) 0/1 (0%) 0/1 (0%) | 1/7 (14.3%) 1/6 (16.7%) 1/7 (14.3%) 1/7 (14.3%) |
| (2.6%) 1/38 (2.6%) 1/37 (2.7%) 3/38 (7.9%) 7/38 (18.4%) 3/38 . | .749 .749 .749 .756 .756 .901 | 1/19 (5.3%) 0/19 (0%) 0/20 (0%) 3/20 (15%) 0/19 | - 0/41 (0%) 4/41 (9.8%) 4/40 (10%) 8/41 (19.5%) | .648 | - | - 2/27 (7.4%) 3/27 (11.1%) 6/27 (22.2%) 3/27 | - 0/6 (0%) 0/6 (0%) 1/6 (16.7%) 0/6 | - 1/1 (100%) 0/1 (0%) 0/1 (0%) | 1/7 (14.3%) 1/6 (16.7%) 1/7 (14.3%) 1/7 |
| (2.6%) 1/38 (2.6%) 1/37 (2.7%) 3/38 (7.9%) 7/38 (18.4%) 3/38 . | .749 .749 .749 .756 .756 .901 | 1/19 (5.3%) 0/19 (0%) 0/20 (0%) 3/20 (15%) 0/19 | - 0/41 (0%) 4/41 (9.8%) 4/40 (10%) 8/41 (19.5%) | .648 | - | - 2/27 (7.4%) 3/27 (11.1%) 6/27 (22.2%) 3/27 | - 0/6 (0%) 0/6 (0%) 1/6 (16.7%) 0/6 | - 1/1 (100%) 0/1 (0%) 0/1 (0%) | 1/7 (14.3%) 1/6 (16.7%) 1/7 (14.3%) 1/7 |
| (2.6%) 1/38 (2.6%) 1/37 (2.7%) 3/38 (7.9%) 7/38 (18.4%) | .749 .749 .749 .756 .756 .901 | 1/19 (5.3%) 0/19 (0%) 0/20 (0%) 3/20 (15%) | - 0/41 (0%) 4/41 (9.8%) 4/40 (10%) 8/41 (19.5%) | .648 | - | 2/27 (7.4%) 3/27 (11.1%) 6/27 (22.2%) | - 0/6 (0%) 0/6 (0%) 1/6 (16.7%) | - 1/1 (100%) 0/1 (0%) 0/1 (0%) | 1/7 (14.3%) 1/6 (16.7%) 1/7 (14.3%) |
| (2.6%) 1/38 (2.6%) 1/37 (2.7%) 3/38 . | .749 | - 1/19 (5.3%) 0/19 (0%) 0/20 | - 0/41 (0%) 4/41 (9.8%) 4/40 | .648 | - | 2/27 (7.4%) 3/27 | 0/6 (0%) 0/6 | - 1/1 (100%) 0/1 | 1/7 (14.3%) 1/6 |
| (2.6%) 1/38 (2.6%) 1/37 (2.7%) | .749 | 1/19 (5.3%) 0/19 (0%) | - 0/41 (0%) 4/41 (9.8%) | .648 | - | - 2/27 (7.4%) | 0/6 (0%) | - 1/1 (100%) | 1/7 (14.3%) |
| (2.6%) 1/38 (2.6%) 1/37 . | .749 | - 1/19 (5.3%) 0/19 | - 0/41 (0%) 4/41 | .648 | - | 2/27 | - 0/6 | - 1/1 | - 1/7 |
| (2.6%) | .749 | - 1 /19 | 0/41 | | - | | | | |
| | .749 | | , , | - | - | - | - | - | |
| | | (5.3%) | (/11/0) | | | | | | |
| 1/37 (2.7%) | .530 | 1 /19 | 3/42 (7.1%) | .902 |] - | 3/28 (10.7%) | 0/6 (0%) | 0/1 (0%) | 0/7 (0%) |
| (26.9%) | · | 0 /11 (0%) | 8/34 (23.5%) | .530 | - | 7/22 (31.8%) | 0/6 | 0/1 (0%) | 1/5 (20%) |
| (21.7%) | 5) | (0%) | (25.8%) | | | (30%) | (16.7%) | (0%) | (25%) |
| (23.1%) 5/23 . | .781 | (0%) 0 /11 | (20.6%) 8/31 | .530 | - | (27.3%) 6/20 | (0%) 1/6 | (0%) 0/1 | (20%) |
| | .749 | (63.6%) 0 /10 | (72.3%) 7/34 | .648 | - | (67.9%) 6/22 | (91.7%) 0/6 | 0/1 | (57.1%) 1/5 |
| | .902 | 14 /22 | 34/47 | .786 | - | 19/28 | 11/12 | - | 4/7 |
| 27/57 (47.4%) | .749 | 15 /22 (68.2%) | 28/51 (54.9%) | .749 | - | 15/32 (46.9%) | 6/11 (54.5%) | 1/1 (100%) | 6/7 (85.7%) |
| 44/61 . (72.1%) | .530 | 19 /24 (79.2%) | 46/50 (92%) | .648 | - | 30/31 (96.8%) | 10/12 (83.3%) | - | 6/7 (85.7%) |
| 56/62 (90.3%) | .786 | 25 /25 (100%) | 51/53 (96.2%) | .749 | - | 32/33 (97%) | 13/13 (100%) | - | 6/7 (85.7%) |
| (78.7%) | | 25 /28 (89.3%) | 45/49 (91.8%) | .901 | - | 32/32 (100%) | 7/10 (70%) | - | 6/7 (85.7%) |
| 28/58 (48.3%) | | 10 /24 (41.6%) | 35 /50 (70%) | .399 | - | (75%) | 3/10 (30%) | 1/1 (100%) | 7/7 (100%) |
| 14.7 | | | | | | | | | |
| | | | | | | | | | 34.6±6.6 |
| · | | 24+ 20 | 27 4+ 20 2 | 786 | 38 | 22.9+19.2 | 32.5+21.7 | 29 3+23 3 | 30.5±19.1 |
| | 19± 20 22± | 14.7 | 19± 20 .530 24± 20 22± .919 22± 8.7 14.7 | 19± 20 .530 24± 20 27.4± 20.2 22± 14.7 .919 22± 8.7 22.8± 15.6 | 19±20 .530 24±20 27.4±20.2 .786 22± 14.7 .919 22±8.7 22.8±15.6 .901 | 19±20 .530 24±20 27.4±20.2 .786 38 22± 14.7 .919 22±8.7 22.8±15.6 .901 28 | 19±20 .530 24±20 27.4±20.2 .786 38 22.9±19.2 22± 14.7 .919 22±8.7 22.8±15.6 .901 28 20.1±14.3 | 19±20 .530 24±20 27.4±20.2 .786 38 22.9±19.2 32.5±21.7 22± 14.7 .919 22±8.7 22.8±15.6 .901 28 20.1±14.3 6.0±2.8 | 19±20 .530 24±20 27.4±20.2 .786 38 22.9±19.2 32.5±21.7 29.3±23.3 22± 14.7 .919 22±8.7 22.8±15.6 .901 28 20.1±14.3 6.0±2.8 3 |

| nsory normalities | 33/73 (45.2%) | 15/35 (42.9%) | 18/38 (47.4%) | .901 | 10 /21 (47.6%) | 19/40 (47.5%) | .993 | - | 12/26 (46.2%) | 3/6 (50%) | 1/1 (100%) | 3/7 (42.9%) |
|-----------------------------|------------------|------------------|------------------|------|-------------------|------------------|------|---|------------------|----------------|---------------|----------------|
| ripheral ropathy | 10/70 (14.3%) | 4/35 (11.4%) | 6/35 (17.1%) | .786 | 2 /20 (10%) | 7/39 (17.9%) | .786 | - | 5/24 (20.8%) | 1/8 (12.5%) | 0/1 (0%) | 1/6 (16.7%) |
| cavus | 16/73 (21.9%) | 9/35 (25.7%) | 7/38 (18.4%) | .786 | 6 /19 (31.6%) | 5/41 (12.2%) | .530 | - | 4/27 (14.8%) | 0/6 (0%) | 0/1 (0%) | 1/7 (14.3%) |
| per remity xia | 4/72 (5.6%) | 1/35 (2.8%) | 3/37 (8.1%) | .749 | 0 /19 (0%) | 4/42 (9.5%) | .648 | - | 2/27 (7.4%) | 1/7 (14.3%) | 0/1 (0%) | 1/7 (14.3%) |
| per remity ent tremor | 2/72 (2.8%) | 0/35 (0%) | 2/37 (5.4%) | .706 | 0 /19 (0%) | 2/42 (4.8%) | .786 | - | 1/27 (3.7%) | 0/7 (0%) | 0/1 (0%) | 1/7 (14.3%) |
| zures | 2/71 (2.8%) | 0/34 (0%) | 2/37 (5.4%) | .749 | 0 /19 (0%) | 1/41 (2.4%) | .786 | - | 1/27 (3.7%) | 0/6 (0%) | 0/1 (0%) | 0/7 (0%) |
| eletal normality | 4/69 (5.8%) | 2/33 (6.1%) | 2/36 (5.5%) | .940 | 0/19 (0%) | 3/40 (7.5%) | .706 | - | 2/27 (7.4%) | 0/6 (0%) | - | 1/7 (14.3%) |
| lower tor neuron | 6/71 (8.5%) | 5/35 (14.3%) | 1/36 (2.8%) | .530 | 1/12 (8.3%) | 3/19 (15.8%) | .843 | - | 3/33 (9.1%) | 0/6 (0%) | - | 1/8 (12.5%) |
| normal in MRI | 6/48 (12.5%) | 4/28 (14.3%) | 2/20 (10%) | .901 | 3 /13 (23.1%) | 3/32 (9.4%) | .706 | - | 2/20 (10%) | 0/5 (0%) | - | 1/7 (14.3%) |
| normal ne MRI | 8/53 (15.1%) | 4/30 (13.3%) | 4/23 (17.4%) | .901 | 2 /15 (13.3%) | 6/32 (18.8%) | .901 | - | 4/17 (23.5%) | 1/9 (11.1%) | - | 1/6 (16.7%) |

^{*} False discovery rate (FDR) correction for multiple comparisons was performed based on 87 tests.

SD, standard deviation; SPRS, Spastic Paraplegia Rating Scale; MRI, magnetic resonance imaging; n, number; LoF, loss of function, MIT, microtubule interacting and trafficking; AAA, ATPase associated with various cellular activities; ATP, adenosine triphosphate.

^a InterPro (IPR) number: IPR036181; ^b IPR003593; ^c IPR041569; ^d IPR015415

Table 2. Mutations identified in the current study and their characteristics.

| | | Number | Number | | AF | |
|-----------------------|-----------------------------|----------------|----------------|---------------|--------------|--------------------------|
| Nucleotide Change | Amino acid Change | of Families | of Patients | AAO (Mean) | in gnomAD | Pathogenicity (VarSome*) |
| c.127G>T | p.(Glu43Ter) | 1 | 1 | UNK | NR | Pathogenic |
| c.153C>G | p.(Tyr51Ter) | 1 | 1 | 1 | NR | Pathogenic |
| c.231G>A | p.(Trp77Ter) | 1 | 1 | 0 | NR | Pathogenic |
| c.562delG | p.(Ala188Profs Ter8) | 1 | 1 | 38 | NR | Pathogenic |
| c.687delT | p.(Ser229Argfs Ter11) | 1 | 1 | 37 | NR | Pathogenic |
| c.869A>G | p.(Lys290Arg) | 1 | 1 | 55 | NR | Likely Pathogenic |
| c.1098delG | p.(Glu366Aspfs Ter28) | 1 | 1 | 42 | NR | Pathogenic |
| c.1111C>T | p.(Leu371Phe) | 2 | 2 | 29 | NR | Pathogenic |
| c.1112T>C | p.(Leu371Pro) | 1 | 1 | 30 | NR | Pathogenic |
| c.1139T>C | p.(Leu380Pro) | 1 | 1 | 28 | NR | Likely Pathogenic |
| c.1144_1145 insGTC | p.(Gly382_Pro383 insArg) | 1 | 2 | 15 | NR | - |
| c.1158T>G | p.(Asn386Lys) | 1 | 1 | 40 | NR | Pathogenic |
| c.1196C>T | p.(Ser399Leu) | 3 | 8 | 33 | NR | Pathogenic |
| c.1209C>A | p.(Phe403Leu) | 2 | 5 | 35 | NR | Likely Pathogenic |
| c.1212_1216del | p.(Asn405Lysfs Ter36) | 1 | 1 | 2 | NR | - |
| c.1220G>A | p.(Ser407Asn) | 1 | 1 | 1 | NR | Pathogenic |
| c.1242A>G | p.(Lys414Lys) | 2 | 3 | 9 | NR | Uncertain significance** |
| c.1276C>G | p.(Leu426Val) | 1 | 1 | 13 | NR | Pathogenic |
| c.1300C>T | p.(Gln434Ter) | 1 | 1 | 40 | NR | Pathogenic |
| c.1321+1G>A | | 1 | 2 | UNK | NR | Pathogenic |
| c.1356_1357 insGGG | p.(Gly452dup) | 1 | 1 | 38 | NR | - |
| c.1378C>T | p.(Arg460Cys) | 1 | 1 | 40 | NR | Pathogenic |
| c.1385A>G | p.(Lys462Arg) | 1 | 1 | 14 | NR | Pathogenic Likely |
| c.1466C>T | p.(Pro489Leu) | 1 | 4 | 19 | NR | Pathogenic |
| c.1492_1493 del | p.(Arg498Alafs Ter30) | 1 | 1 | 50 | NR | Pathogenic |

| c.1493+2T>A | | 1 | 1 | 39 | NR | Pathogenic |
|------------------|-------------------------|---|----|-----|----------|----------------------|
| c.1495C>T | p.(Arg499Cys) | 2 | 4 | 6 | NR | Pathogenic |
| c.1496G>A | p.(Arg499His) | 4 | 4 | 2 | NR | Pathogenic |
| c.1507C>T | p.(Arg503Trp) | 3 | 4 | 34 | 4.82E-06 | Pathogenic |
| c.1537-2A>G | | 1 | 7 | 17 | NR | Pathogenic |
| c.1610T>G | p.(Leu537Arg) | 1 | 1 | UNK | NR | Pathogenic |
| c.1676G>A | p.(Gly559Asp) | 8 | 15 | 33 | NR | Pathogenic |
| c.1684C>T | p.(Arg562Ter) | 1 | 2 | 10 | NR | Pathogenic |
| c.1685G>A | p.(Arg562Gln) | 1 | 1 | 65 | NR | Pathogenic |
| c.1729-1G>C | | 2 | 2 | 27 | NR | Pathogenic |
| c.1741C>T | p.(Arg581Ter) | 2 | 2 | 42 | 4.81E-06 | Pathogenic |
| c.1790delG | p.(Ser597Thrfs Ter3) | 1 | 3 | 4 | NR | Pathogenic |
| c.1844C>T | p.(Thr615Ile) | 1 | 1 | 30 | NR | Likely Pathogenic |
| del exon 1 | | 3 | 3 | 42 | NR | Pathogenic |
| del exons 5-7 | | 1 | 2 | UNK | NR | Pathogenic |
| del exons 16-17 | | 1 | 1 | UNK | NR | Pathogenic |

AAO, age at onset; UNK, unknown; NR, not reported; AF, allele frequency.

^{*} American College of Medical Genetics and Genomics (ACMG)

^{**} Mutations with uncertain significance were included with the condition of being rare and cosegregation with the disease.

Table 3. Frequency of symptoms not attributable to the pure form of hereditary spastic paraplegia in the present study compared to previous studies.

| Sign/ Symptom | Frequency in the current study | Previous studies |
|-----------------------------|--------------------------------|------------------------------|
| Learning disabilities | 19.6% | 4.2% intellectual |
| | | impairment ¹ |
| | | 1.5% Intellectual |
| | | disability ² |
| Speech delay or abnormality | 17% | 4/62 (6.5%) ² |
| Dysarthria | 16.4% | 3% ² |
| Cognitive deficiency | 8.2% | Most frequent |
| | | additional |
| | | manifestation ³⁻⁷ |
| Upper extremity | 2.8% | Mild arm tremor in |
| intention tremor | | 10% of patients ² |
| Seizure | 2.8% | Case reports 8-11 |
| | | |
| Ocular movement abnormality | 1.4% | Case reports ¹² |
| Swallowing difficulty | 5.6% | 3% ² |
| Upper limb weak | 6.9% | Case reports ⁵ |
| ness | | |
| Upper limb ataxia | 5.6% | Case reports ⁵ |
| Peripheral | 14.3% | Case reports ¹³ |
| neuropathy | | |
| | | |
| Deafness | 5.6% | - |

References

- 1. Parodi L, Fenu S, Barbier M, et al. Spastic paraplegia due to SPAST mutations is modified by the underlying mutation and sex. *Brain*. 2018;141(12):3331-3342.
- 2. de Bot ST, van den Elzen RT, Mensenkamp A, et al. Hereditary spastic paraplegia due to SPAST mutations in 151 Dutch patients: new clinical aspects and 27 novel mutations. *Journal of Neurology, Neurosurgery & Psychiatry.* 2010;81(10):1073-1078.
- 3. Murphy S, Gorman G, Beetz C, et al. Dementia in SPG4 hereditary spastic paraplegia: clinical, genetic, and neuropathologic evidence. *Neurology*. 2009;73(5):378-384.
- 4. Ribaï P, Depienne C, Fedirko E, et al. Mental deficiency in three families with SPG4 spastic paraplegia. *European journal of human genetics*. 2008;16(1):97-104.
- 5. Nielsen J, Johnsen B, Koefoed P, et al. Hereditary spastic paraplegia with cerebellar ataxia: a complex phenotype associated with a new SPG4 gene mutation. *European journal of neurology*. 2004;11(12):817-824.
- 6. Tallaksen CM, Guichart-Gomez E, Verpillat P, et al. Subtle cognitive impairment but no dementia in patients with spastin mutations. *Archives of neurology*. 2003;60(8):1113-1118.
- 7. Chamard L, Ferreira S, Pijoff A, Silvestre M, Berger E, Magnin E. Cognitive impairment involving social cognition in SPG4 hereditary spastic paraplegia. *Behavioural neurology*. 2016;2016.
- 8. Mead S, Proukakis C, Wood N, Crosby A, Plant G, Warner T. A large family with hereditary spastic paraparesis due to a frame shift mutation of the spastin (SPG4) gene: association with multiple sclerosis in two affected siblings and epilepsy in other affected family members. *Journal of Neurology, Neurosurgery & Psychiatry*. 2001;71(6):788-791.
- 9. Orlacchio A, Kawarai T, Totaro A, et al. Hereditary spastic paraplegia: clinical genetic study of 15 families. *Archives of Neurology*. 2004;61(6):849-855.
- 10. Orlacchio A, Gaudiello F, Totaro A, et al. A new SPG4 mutation in a variant form of spastic paraplegia with congenital arachnoid cysts. *Neurology*. 2004;62(10):1875-1878.
- 11. Cruz-Camino H, Vázquez-Cantú M, Vázquez-Cantú DL, et al. Clinical Characterization of 2 Siblings with a Homozygous SPAST Variant. *The American journal of case reports*. 2020;21:e919463-919461.
- 12. Guthrie G, Pfeffer G, Bailie M, et al. The neurological and ophthalmological manifestations of SPG4-related hereditary spastic paraplegia. *Journal of neurology*. 2013;260(3):906-909.
- 13. Kumar KR, Sue CM, Burke D, Ng K. Peripheral neuropathy in hereditary spastic paraplegia due to spastin (SPG4) mutation—a neurophysiological study using excitability techniques. *Clinical neurophysiology*. 2012;123(7):1454-1459.